Infarktbedingter kardiogener Schock

Matthias Eden; Norbert Frey

doi:10.1055/a-0719-9601

Intensivmedizin up2date, Table of Contents

Intensivmedizin up2date 2019; 15(03): 311-325
DOI: 10.1055/a-0719-9601

Internistische Intensivmedizin

Georg Thieme Verlag KG Stuttgart · New York

Infarktbedingter kardiogener Schock

Authors

Matthias Eden
Norbert Frey

Abstract

All articles of this category

Der kardiogene Schock ist ein lebensbedrohlicher Zustand, der als Komplikation des akuten Myokardinfarktes in etwa 5 – 15% aller Fälle auftreten kann. Das frühzeitige Erkennen und die erfolgreiche Behandlung der auslösenden Ursache im Sinne einer umgehenden Revaskularisation und die Sicherstellung einer adäquaten Organperfusion entscheiden über die Prognose. Dennoch beträgt trotz aufwendiger Therapie die Letalität des kardiogenen Schocks immer noch nahezu 50%.

Schlüsselwörter

kardiogener Schock - zeitnahe Reperfusion - Zugangsweg - mechanische Herz-Kreislauf-Unterstützung - ECLS - ECMO - Impella - Cardiac Arrest Center - Multiorgandysfunktionssyndrom

Full Text

References

Literatur
1 Thiele H, Ohman EM, Desch S. et al. Management of cardiogenic shock. Eur Heart J 2015; 36: 1223-1230 doi:10.1093/eurheartj/ehv051
2 Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117: 686-697 doi:10.1161/CIRCULATIONAHA.106.613596
3 Reyentovich A, Barghash MH, Hochman JS. Management of refractory cardiogenic shock. Nat Rev Cardiol 2016; 13: 481-492 doi:10.1038/nrcardio.2016.96
4 Hochman JS, Sleeper LA, Webb JG. et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634 doi:10.1056/NEJM199908263410901
5 Mebazaa A, Combes A, van Diepen S. et al. Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med 2018; 44: 760-773 doi:10.1007/s00134-018-5214-9
6 Ashruf JF, Bruining HA, Ince C. New insights into the pathophysiology of cardiogenic shock: the role of the microcirculation. Curr Opin Crit Care 2013; 19: 381-386 doi:10.1097/MCC.0b013e328364d7c8
7 Lim HS. Cardiogenic shock: failure of oxygen delivery and oxygen utilization. Clin Cardiol 2016; 39: 477-483 doi:10.1002/clc.22564
8 Lima A. Current status of tissue monitoring in the management of shock. Curr Opin Crit Care 2016; 22: 274-278 doi:10.1097/MCC.0000000000000300
9 Prondzinsky R, Unverzagt S, Lemm H. et al. Acute myocardial infarction and cardiogenic shock: prognostic impact of cytokines: INF-gamma, TNF-alpha, MIP-1beta, G-CSF, and MCP-1beta. Med Klin Intensivmed Notfmed 2012; 107: 476-484 doi:10.1007/s00063-012-0117-y
10 McLean AS. Echocardiography in shock management. Crit Care 2016; 20: 275 doi:10.1186/s13054-016-1401-7
11 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) 2015; 68: 1125 doi:10.1016/j.rec.2015.10.009
12 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619 doi:10.1093/eurheartj/ehs215
13 Thiele H, Akin I, Sandri M. et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med 2017; 377: 2419-2432 doi:10.1056/NEJMoa1710261
14 Roule V, Lemaitre A, Sabatier R. et al. Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: A radial-first centre experience and meta-analysis of published studies. Arch Cardiovasc Dis 2015; 108: 563-575 doi:10.1016/j.acvd.2015.06.005
15 Hauffe T, Kruger B, Bettex D. et al. Shock management for cardio-surgical ICU patients – the golden hours. Card Fail Rev 2015; 1: 75-82 doi:10.15420/cfr.2015.1.2.75
16 Friesecke S, Heinrich A, Abel P. et al. Comparison of pulmonary artery and aortic transpulmonary thermodilution for monitoring of cardiac output in patients with severe heart failure: validation of a novel method. Crit Care Med 2009; 37: 119-123 doi:10.1097/CCM.0b013e31819290d5
17 De Backer D, Biston P, Devriendt J. et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789 doi:10.1056/NEJMoa0907118
18 Moller MH, Granholm A, Junttila E. et al. Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 2018; 62: 420-450 doi:10.1111/aas.13089
19 Schumann J, Henrich EC, Strobl H. et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2018; (01) CD009669
20 Buerkem B, Lemm H, Krohe K. et al. Levosimendan in the treatment of cardiogenic shock. Minerva Cardioangiol 2010; 58: 519-530
21 Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014; 63: 2069-2078 doi:10.1016/j.jacc.2014.01.016
22 Nieminen MS, Buerke M, Cohen-Solal A. et al. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. Int J Cardiol 2016; 218: 150-157 doi:10.1016/j.ijcard.2016.05.009
23 Fuhrmann JT, Schmeisser A, Schulze MR. et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 2008; 36: 2257-2266 doi:10.1097/CCM.0b013e3181809846
24 Leopold V, Gayat E, Pirracchio R. et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 2018; 44: 847-856 doi:10.1007/s00134-018-5222-9
25 Levy B, Clere-Jehl R, Legras A. et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2018; 72: 173-182 doi:10.1016/j.jacc.2018.04.051
26 Tarvasmaki T, Lassus J, Varpula M. et al. Current real-life use of vasopressors and inotropes in cardiogenic shock – adrenaline use is associated with excess organ injury and mortality. Crit Care 2016; 20: 208 doi:10.1186/s13054-016-1387-1
27 Thiele H, Zeymer U, Neumann FJ. et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-1296 doi:10.1056/NEJMoa1208410
28 Napp LC, Kühn C, Bauersachs J. ECMO in cardiac arrest and cardiogenic shock. Herz 2017; 42: 27-44 doi:10.1007/s00059-016-4523-4
29 Ostadal P, Rokyta R, Kruger A. et al. Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. Eur J Heart Fail 2017; 19 Suppl 2: 124-127 doi:10.1002/ejhf.857
30 Ouweneel DM, Schotborgh JV, Limpens J. et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 2016; 42: 1922-1934 doi:10.1007/s00134-016-4536-8
31 Overtchouk P, Pascal J, Lebreton G. et al. Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. EuroIntervention 2018; 13: e2160-e2168 doi:10.4244/EIJ-D-17-01014
32 Beurtheret S, Mordant P, Paoletti X. et al. Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 2013; 34: 112-120 doi:10.1093/eurheartj/ehs081
33 Lauten A, Engstrom AE, Jung C. et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6: 23-30 doi:10.1161/CIRCHEARTFAILURE.112.967224
34 Lazkani M, Murarka S, Kobayashi A. et al. A retrospective analysis of Impella use in all-comers: 1-year outcomes. J Interv Cardiol 2017; 30: 577-583 doi:10.1111/joic.12409
35 Vase H, Christensen S, Christiansen A. et al. The Impella CP device for acute mechanical circulatory support in refractory cardiac arrest. Resuscitation 2017; 112: 70-74 doi:10.1016/j.resuscitation.2016.10.003
36 Schrage B, Ibrahim K, Loehn T. et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation 2019; 139: 1249-1258 doi:10.1161/CIRCULATIONAHA.118.036614
37 Pappalardo F, Schulte C, Pieri M. et al. Concomitant implantation of Impella(R) on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 2017; 19: 404-412 doi:10.1002/ejhf.668
38 Basir MB, Schreiber TL, Grines CL. et al. Effect of early initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol 2017; 119: 845-851 doi:10.1016/j.amjcard.2016.11.037
39 Esposito ML, Kapur NK. Acute mechanical circulatory support for cardiogenic shock: the “door to support” time. F1000Res 2017; 6: 737 doi:10.12688/f1000research.11150.1
40 Pellis T, Sanfilippo F, Ristagno G. The optimal hemodynamics management of post-cardiac arrest shock. Best Pract Res Clin Anaesthesiol 2015; 29: 485-495 doi:10.1016/j.bpa.2015.10.002
41 Hongisto M, Lassus J, Tarvasmaki T. et al. Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. Int J Cardiol 2017; 230: 191-197 doi:10.1016/j.ijcard.2016.12.175
42 Annborn M, Bro-Jeppesen J, Nielsen N. et al. The association of targeted temperature management at 33 and 36 degrees C with outcome in patients with moderate shock on admission after out-of-hospital cardiac arrest: a post hoc analysis of the Target Temperature Management trial. Intensive Care Med 2014; 40: 1210-1219 doi:10.1007/s00134-014-3375-8
43 Marenzi G, Assanelli E, Campodonico J. et al. Acute kidney injury in ST-segment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010; 38: 438-444 doi:10.1097/CCM.0b013e3181b9eb3b
44 Marenzi G, Cosentino N, Marinetti A. et al. Renal replacement therapy in patients with acute myocardial infarction: Rate of use, clinical predictors and relationship with in-hospital mortality. Int J Cardiol 2017; 230: 255-261 doi:10.1016/j.ijcard.2016.12.130
45 van Diepen S, Reynolds HR, Stebbins A. et al. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med 2014; 42: 281-288 doi:10.1097/CCM.0b013e31829f6242
46 Barilla F, Pannarale G, Torromeo C. et al. Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study. Clin Drug Investig 2016; 36: 849-856 doi:10.1007/s40261-016-0424-9
47 Holst LB, Haase N, Wetterslev J. et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014; 371: 1381-1391 doi:10.1056/NEJMoa1406617
48 Schober A, Sterz F, Laggner AN. et al. Admission of out-of-hospital cardiac arrest victims to a high volume cardiac arrest center is linked to improved outcome. Resuscitation 2016; 106: 42-48 doi:10.1016/j.resuscitation.2016.06.021
49 Aissaoui N, Puymirat E, Simon T. et al. Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Registry. Crit Care 2014; 18: 516 doi:10.1186/s13054-014-0516-y